8-K
filed May 12, 2025, 7:59 PM ET
ticker HEPA
CIK 0001583771
other material
confidence high
sentiment negative
materiality 0.90
Hepion Pharmaceuticals, Inc. (HEPA): Nasdaq/NYSE listing notice — Hepion delisted from Nasdaq; pivots to diagnostics via New Day license
Hepion Pharmaceuticals, Inc.
- Received Nasdaq delisting notice for failing to maintain $1.00 bid price and being deemed a public shell; trading suspended May 13, 2025.
- Expects common stock to trade on OTC Markets under symbol HEPA after suspension.
- Entered license agreement with New Day Diagnostics on May 9, 2025, for diagnostic tests (celiac, respiratory multiplex, H. pylori, HCC).
- Celiac, respiratory, and H. pylori tests have CE marks and are eligible for sale in Europe.
Key facts
Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.96
Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5550(a)(2), 5101).
- Exchange
- nasdaq
- Notice
- delisting notice
- Rules
- 5550(a)(2), 5101
Exact text from the filing
May 9, 2025, Hepion Pharmaceuticals, Inc. (the “Company) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the Company is a public s
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.97
Hepion Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5101).
- Exchange
- nasdaq
- Notice
- delisting notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2), 5101
Exact text from the filing
May 9, 2025, Hepion Pharmaceuticals, Inc. (the “Company) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the Company is a public s
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.